Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Toby Eyre

Toby Eyre

MBChB (Hons), MRCP (UK), FRCPath (UK), MD
Oxford University Hospitals NHS Foundation Trust
Advancing treatment for patients with Richter’s transformation 3:07
Advancing treatment for patients with Richter’s transformation
Toby Eyre • 29 Nov 2023
Induction & maintenance therapy in elderly patients with MCL: insights from the MCL-R2 Elderly trial 3:07
Induction & maintenance therapy in elderly patients with MCL: insights from the MCL-R2 Elderly trial
Toby Eyre • 29 Nov 2023
The BOVen trial: MRD-guided obinutuzumab, zanubrutinib and venetoclax regimen in TP53-mutated MCL 2:38
The BOVen trial: MRD-guided obinutuzumab, zanubrutinib and venetoclax regimen in TP53-mutated MCL
Toby Eyre • 29 Nov 2023
FLAIR trial: improved outcomes with MRD-guided ibrutinib plus venetoclax in CLL compared to FCR 3:00
FLAIR trial: improved outcomes with MRD-guided ibrutinib plus venetoclax in CLL compared to FCR
Toby Eyre • 29 Nov 2023
Long-term safety analysis of pirtobrutinib in R/R B-cell malignancies 1:11
Long-term safety analysis of pirtobrutinib in R/R B-cell malignancies
Toby Eyre • 16 Jun 2023
BRUIN CLL-322 update: fixed-duration pirtobrutinib plus VR vs VR in patients with R/R CLL 1:00
BRUIN CLL-322 update: fixed-duration pirtobrutinib plus VR vs VR in patients with R/R CLL
Toby Eyre • 16 Jun 2023
MAIC of pirtobrutinib vs venetoclax in patients with R/R CLL previously treated with a covalent BTKi 1:48
MAIC of pirtobrutinib vs venetoclax in patients with R/R CLL previously treated with a covalent BTKi
Toby Eyre • 16 Jun 2023
Hot updates in R/R MCL at ASH 2022: data on pirtobrutinib, glofitamab & zilovertamab 4:51
Hot updates in R/R MCL at ASH 2022: data on pirtobrutinib, glofitamab & zilovertamab
Toby Eyre • 21 Nov 2022
Ongoing trials investigating the efficacy of pirtobrutinib in CLL 2:14
Ongoing trials investigating the efficacy of pirtobrutinib in CLL
Toby Eyre • 21 Nov 2022
Comparison of the different BTK inhibitors available & under investigation in frontline and R/R CLL 3:42
Comparison of the different BTK inhibitors available & under investigation in frontline and R/R CLL
Toby Eyre • 21 Nov 2022
The impact of comorbidity burden on treatment decisions in CLL 1:26
The impact of comorbidity burden on treatment decisions in CLL
Toby Eyre • 21 Nov 2022
Ibrutinib’s role in CLL treatment and future outlooks 2:14
Ibrutinib’s role in CLL treatment and future outlooks
Toby Eyre • 15 Jun 2022
Prognostic markers in MCL and the value of CAR-T therapy in treating high-risk disease 1:59
Prognostic markers in MCL and the value of CAR-T therapy in treating high-risk disease
Toby Eyre • 15 Jun 2022
Some insights into BRUIN CLL-322: a trial in progress 1:43
Some insights into BRUIN CLL-322: a trial in progress
Toby Eyre • 15 Jun 2022
Updates from the Phase I/II BRUIN study: pirtobrutinib in CLL 2:39
Updates from the Phase I/II BRUIN study: pirtobrutinib in CLL
Toby Eyre • 15 Jun 2022
Outcomes of CLL patients following treatment with a covalent BTK and BCL2 inhibitor 1:19
Outcomes of CLL patients following treatment with a covalent BTK and BCL2 inhibitor
Toby Eyre • 15 Jun 2022
The content of VJHemOnc is intended for healthcare professionals